ReviewMedical journal of the Islamic Republic of Iran2016
The importance of BRCA1 and BRCA2 genes mutations in breast cancer development.
Review in Medical journal of the Islamic Republic of Iran, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Occupational Exposure to Benzene and Risk of Breast Cancer: Systematic Review and Meta-Analysis.La Medicina del lavoro · 2024Pooled it
- Pooled it
- Community-Based Hereditary Breast and Ovarian Cancer Family History Assessment and Genetic Testing among Spanish-Speaking Hispanic/Latina Women in California.Cancer research communications · 2026Article
- Review
- Scoring System for Predicting Breast Cancer Risk Among Women in Regions with Limited Healthcare Infrastructure in Indonesia.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Comparing Disease-Free Survival (DFS) and Overall Survival (OS) Rates in Breast Cancer Patients: Axillary Lymph Node Dissection (ALND) Versus Sentinel Lymph Node Biopsy (SLNB).International journal of breast cancer · 2026Article
- Fueling the Seed: Growth Factors and Cytokines Driving Cancer Stem Cells in Gynecological Malignancies.International journal of molecular sciences · 2025Review
- Innovative nanodelivery systems for targeted breast cancer therapy: overcoming drug delivery challenges and exploring future perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A network model for patient-derived drug response in breast cancer integrating multi-omics datasets.bioRxiv : the preprint server for biology · 2025Article
- Breast cancer incidence in Indonesia: a sex-disaggregated analysis using WHO health equity assessment toolkit data.BMC cancer · 2025Article
- Associations Between DNA Repair Gene Polymorphisms and Breast Cancer Histopathological Subtypes: A Preliminary Study.Journal of clinical medicine · 2025Article
- A smartphone-colorimetric dual-mode diagnosis method for breast cancer detection of BRCA-1 gene base on silver plated substrate and catalytic hairpin assembly amplification.Journal of nanobiotechnology · 2025Article
- Current practices and challenges in genetic testing and counseling for women with breast and ovarian cancer in Asia.Asia-Pacific journal of clinical oncology · 2025Article
- BRCA1 and BRCA2 Gene Mutations in Reproductive-Aged Women With Polycystic Ovarian Syndrome.Cureus · 2025Article
- Exploring thymic stromal lymphopoietin in the breast cancer microenvironment: A preliminary study.Oncology letters · 2025Article
- Association between single nucleotide polymorphisms of DNA repair genes (BRCA1, BRCA2, and PALB2) and breast cancer incidence in a subset of Iranian population.Hereditary cancer in clinical practice · 2025Article
- Unraveling the role of withanolides as key modulators in breast cancer mitigation.Molecular biology reports · 2025Review
- Article
- Unraveling the influence of α-mangostin on MDA-MB-231 cell line via WNT/β-catenin signaling pathway:Frontiers in pharmacology · 2025Article
- Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many factors including genetic, environmental, and acquired are involved in breast cancer development across various societies. Among all of these factors in families with a history of breast cancer throughout several generations, genetics, like predisposing genes to develop this disease, should be considered more. Early detection of mutation carriers in these genes, in turn, can play an important role in its prevention. Because this disease has a high prevalence in half of the global population, female screening of reported mutations in predisposing genes, which have been seen in breast cancer patients, seems necessary. In this review, a number of mutations in two predisposing genes (BRCA1 and BRCA2) that occurred in patients with a family history was investigated. We studied published articles about mutations in genes predisposed to breast cancer between 2000 and 2015. We then summarized and classified reported mutations in these two genes to recommend some exons which have a high potential to mutate. According to previous studies, exons have been reported as most mutated exons presented in this article. Considering the large size and high cost of screening all exons in these two genes in patients with a family history, especially in developing countries, the results of this review article can be beneficial and helpful in the selection of exon to screen for patients with this disease.
Indexed as
Identifiers
27493913PMC4972064What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.